Muutke küpsiste eelistusi

Clinical Ophthalmic Oncology: Uveal Tumors Fourth Edition 2025 [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 371 pages, kõrgus x laius: 279x210 mm, 362 Illustrations, color; 26 Illustrations, black and white; IV, 371 p. 388 illus., 362 illus. in color., 1 Hardback
  • Ilmumisaeg: 03-May-2025
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3031813537
  • ISBN-13: 9783031813535
Teised raamatud teemal:
  • Kõva köide
  • Hind: 187,67 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 220,79 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 371 pages, kõrgus x laius: 279x210 mm, 362 Illustrations, color; 26 Illustrations, black and white; IV, 371 p. 388 illus., 362 illus. in color., 1 Hardback
  • Ilmumisaeg: 03-May-2025
  • Kirjastus: Springer International Publishing AG
  • ISBN-10: 3031813537
  • ISBN-13: 9783031813535
Teised raamatud teemal:
Written by internationally renowned experts, this book is the newest volume in the Clinical Ophthalmic Oncology book series. This book, in addition to the other six volumes provides detailed practical guidance and advice on the diagnosis and management of the complete range of ocular cancers. Supplying the reader with state-of-the-art knowledge required in order to identify these cancers early and to treat them as effectively as possible, this book covers Uveal Tumors. The information presented enables readers to provide effective patient care using the latest knowledge on ophthalmic oncology and to verify diagnostic conclusions based on comparison with numerous full-color clinical photographs from the authors' private collections, histopathologic microphotographs, imaging studies, crisp illustrations, and videos.





 





Clinical Ophthalmic Oncology's clinically focused and user-friendly format allows for rapid retrieval of information in daily practice and is written for residents, fellows, and any physician involved in the care of patients with ocular or orbital malignancies. Additionally, this edition adds several hundred new images to improve comprehension of procedures and techniques. This volume is devoted solely to uveal tumors, explaining various diagnostic and biopsy techniques (videos), and describing the therapeutic options for different types of uveal tumors and their simulating conditions.
Ch. 1: Uveal Tumors: Examination Techniques.- Ch. 2: Classification of
Uveal Tumors.- Ch. 3: Benign Melanocytic Tumors of the Uveal.- Ch. 4: Benign
Melanocytic Tumors of the Posterior Uvea.- Ch. 5: Uveal Melanoma:
Epidemiologic Aspects.- Ch. 6: BAP1 predisposition syndrome.- Ch. 7: Uveal
Melanoma: Clinical Features.- Ch. 8: Uveal Melanoma: Differential Diagnosis.-
Ch. 9: Uveal Melanoma: Histopathologic Features.- Ch.10: Uveal Melanoma:
Molecular Pathology.- Ch. 11: Animal Models in Uveal Melanoma.- Ch. 12: Iris
Melanoma.- Ch. 13: Management of Patients with Posterior Uveal Melanoma.- Ch.
14: Uveal Melanoma: Brachytherapy.- Ch. 15: Uveal Melanoma: Proton Beam
Radiation Therapy.- Ch. 16: Uveal Melanoma: Stereotactic Radiation Therapy.-
Ch. 17: Radiation Retinopathy.- Ch. 18: Radiation Optic Neuropathy.- Ch. 19:
Uveal Melanoma: Phototherapy.- Ch. 20: Uveal Melanoma: Resection Techniques.-
Ch. 21: Uveal Melanoma: The Collaborative Ocular Melanoma Study.- Ch. 22:
Uveal Melanoma: Prognostic Factors .- Ch. 23: Uveal Melanoma: Prognostication
Methods.- Ch. 24: Uveal Melanoma: Mortality.- Ch. 25: Uveal Melanoma: Role of
Biomarkers.- Ch. 26: Uveal Melanoma: Adjuvant Therapy.- Ch. 27: Uveal
Melanoma: Metastases.- Ch. 28: Uveal Vascular Tumors.- Ch. 29: Uveal Neural
Tumors.- Ch. 30: Intraocular Manifestations of Hematopoietic Disorders.- Ch.
31: Uveal Myogenic, Fibro-histiocytic and Histiocytic Tumors.- Ch. 32: Uveal
Lymphoproliferative Tumors.- Ch. 33: Uveal Metastatic Tumors.- Ch. 34: Uveal
Osseous Tumors.- Ch. 35: Bilateral Diffuse Uveal Melanocytic Proliferation.
Arun D. Singh, MD Director, Department of Ophthalmic Oncology Cole Eye Institute, Cleveland Clinic Cleveland, Ohio USA 



Bertil E. Damato, MD, PhDSenior Clinical Research FellowUniversity of OxfordNuffield Department of Clinical Neurosciences, John Radcliffe HospitalOxford, UK